Depemokimab as an Extended treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease

Short Title: ENDURA-1

Enrollment Status: Recruiting

NCT #: NCT06959095

Specialty Area: Pulmonology

Condition Studied: Chronic Obstructive Pulmonary Disease (COPD)

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To evaluate the efficacy of depemokimab 100 mg SC compared with placebo, given every 26 weeks

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 40-80 years of age
Diagnosed with moderate to severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations
Current or former cigarette smoker
No asthma diagnosis
No primary pulmonary hypertension

What's Involved

Participation in the study will include:

Medication administered by injection under the skin

Principal Investigator

Farah Madhani-Lovely, MD

Critical Care Medicine

A Member of

(775) 982–5000

Renown Medical Group – Pulmonary Medicine

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06959095

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews